The EMA is implementing major changes to accelerate drug approvals in the EU, addressing delays that affect patients and businesses alike. Following a turbulent period marked by Brexit and the ...

The EMA's human medicines committee (CHMP ... "As the pandemic evolves, the EU's strategy is to have a broad range of adapted vaccines that target different SARS-CoV-2 variants so member states ...